Trial Profile
Phase II Study of the Combination of Low-Intensity Chemotherapy and Blinatumomab in Patients With Philadelphia Chromosome Negative Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2022
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Mercaptopurine (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Rituximab (Primary) ; Vincristine (Primary) ; Dexamethasone; Dexamethasone; Filgrastim; Folinic acid; Folinic acid; Mesna; Pegfilgrastim; Prednisone
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 03 Nov 2022 Status changed from completed to discontinued.
- 08 Jun 2021 Status changed from recruiting to completed.
- 22 Jan 2020 Planned End Date changed from 13 Dec 2019 to 31 Dec 2035.